Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Darnell JE Jr. STATs and gene regulation. Science277,1630–1635 (1997).
  Medline CASGoogle Scholar
• 2  Bromberg J, Darnell JE. The role of STATs in transcriptional control and their impact on cellular function. Oncogene19,2468–2473 (2000).
  Medline CASGoogle Scholar
• 3  Darnell JE Jr. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer2,740–749 (2002).▪ Underlines the role of signal transducer and activator of transcription (STAT) as a target for cancer therapy.
  Medline CASGoogle Scholar
• 4  Yu H, Jove R. The STATs of cancer – new molecular targets come of age. Nat. Rev. Cancer4,97–105 (2004).
  Medline CASGoogle Scholar
• 5  Krebs DL, Hilton DJ. SOCS: physiological suppressors of cytokine signaling. J. Cell Sci.113(Pt. 16),2813–2819 (2000).
  Medline CASGoogle Scholar
• 6  Isomoto H, Mott JL, Kobayashi S. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology132(1),384–396 (2007).
  Medline CASGoogle Scholar
• 7  Shuai K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene21,2638–2644 (2000).
  Google Scholar
• 8  Shuai K, Liu B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat. Rev. Immunol.5,593–605 (2005).
  Medline CASGoogle Scholar
• 9  Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Annu. Rev. Immunol.18,143–164 (2000).
  Medline CASGoogle Scholar
• 10  Daino H, Matsumura I, Takada K et al. Induction of apoptosis by extracellular ubiquitin in human hematopoietic cells: possible involvement of STAT3 degradation by proteasome pathway in interleukin 6-dependent hematopoietic cells. Blood95,2577–2585 (2000).
  Medline CASGoogle Scholar
• 11  Yamada S, Shiono S, Joo A, Yoshimura A. Control mechanism of JAK/STAT signal transduction pathway. FEBS Lett.534,190–196 (2003).
  Medline CASGoogle Scholar
• 12  Woetmann A, Nielsen M, Christensen ST et al. Inhibition of protein phosphatase 2A induces serine/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3. Proc. Natl Acad. Sci.96,10620–10625 (1999).
  Medline CASGoogle Scholar
• 13  Tanaka T, Soriano MA, Grusby MJ. SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling. Immunity22,729–736 (2005).
  Medline CASGoogle Scholar
• 14  Wegenka UM, Buschmann J, Lutticken C, Heinrich PC, Horn F. Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the post translational level. Mol. Cell. Biol.13,276–288 (1993).
  Medline CASGoogle Scholar
• 15  Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signaling through the gp130/Jak/STAT pathway. Biochem. J.334,297–314 (1998).
  Medline CASGoogle Scholar
• 16  Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene19,2548–2556 (2000).
  Medline CASGoogle Scholar
• 17  Zhang Z, Fuller GM. The competitive binding of STAT3 and NF-κB on an overlapping DNA binding site. Biochem. Biophys. Res. Commun.237,90–94 (1997).
  MedlineGoogle Scholar
• 18  Takeda K, Clausen BE, Kaisho T et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of STAT3 in macrophages and neutrophils. Immunity10,39–49 (1999).
  Medline CASGoogle Scholar
• 19  Pardoll DM. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol.21,807–839 (2003).
  Medline CASGoogle Scholar
• 20  Wang T, Niu G, Kortylewski M et al. Regulation of the innate and adaptive immune responses by STAT3 signaling in tumor cells. Nature Med.10,48–54 (2004).
  MedlineGoogle Scholar
• 21  Cheng F, Wang HW, Cuenca A et al. Critical role for STAT3 signaling in immune tolerance. Immunity19,425–436 (2003).
  Medline CASGoogle Scholar
• 22  Grandis JR, Drenning SD, Zeng Q et al. Constitutive activation of STAT3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl Acad. Sci.97,4227–4232 (2000).
  Medline CASGoogle Scholar
• 23  Niu G, Bowman T, Huang M et al. Roles of activated Src and STAT3 signaling in melanoma tumor cell growth. Oncogene21,7001–7010 (2002).
  Medline CASGoogle Scholar
• 24  Catlett-Falcone R, Landowski TH, Oshiro MM et al. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity10,105–115 (1999).
  Medline CASGoogle Scholar
• 25  Epling-Burnette PK, Liu JH, Catlett-Falcone R et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest.107,351–362 (2001).
  Medline CASGoogle Scholar
• 26  Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood101,1535–1542 (2003).
  Medline CASGoogle Scholar
• 27  Shen Y, Devgan G, Darnell JE Jr, Bromberg JF. Constitutively activated STAT3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated STAT1. Proc. Natl Acad. Sci.98,1543–1548 (2001).
  Medline CASGoogle Scholar
• 28  Prendergast GC. Mechanisms of apoptosis by c-Myc. Oncogene18,2967–2987 (1999).
  Medline CASGoogle Scholar
• 29  Bowman T, Broome MA, Sinibaldi D et al. STAT3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl Acad. Sci.98,7319–7324 (2001).
  Medline CASGoogle Scholar
• 30  Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res.8,945–954 (2002).
  Medline CASGoogle Scholar
• 31  Kijima T, Niwa H, Steinman RA et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ.13,355–362 (2002).
  Medline CASGoogle Scholar
• 32  Masuda M, Suzui M, Yasumatu R et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res.62,3351–3355 (2002).
  Medline CASGoogle Scholar
• 33  Sinibaldi D, Wharton W, Turkson J, Bowman T, Pledger WJ, Jove R. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene19,5419–5427 (2000).
  Medline CASGoogle Scholar
• 34  Vogelstein B, Lane D, Levine AJ. The p53 tumor-suppressor gene integrates numerous signals that control cell life and death. As when a highly connected node in the Internet breaks down, the disruption of p53 has severe consequences. Nature408,307–310 (2000).
  Medline CASGoogle Scholar
• 35  Mora LB, Buettner R, Seigne J et al. Constitutive activation of STAT3 in human prostate tumors and cell lines direct inhibition of STAT3 signaling induces apoptosis of prostate cancer cells. Cancer Res.62,6659–6666 (2002).
  Medline CASGoogle Scholar
• 36  Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene19,2474–2488 (2000).
  Medline CASGoogle Scholar
• 37  Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b, via PTEN and CYLD, are part of the epigenetic switch linking inflammation to cancer. Mol. Cell39,493–506 (2010).
  Medline CASGoogle Scholar
• 38  Hanahan D, Weinberg RA. The hallmarks of cancer. Cell100,57–70 (2000).
  Medline CASGoogle Scholar
• 39  Rak J, Yu JL, Klement G, Kerbel RS. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J. Invest. Derm.5,24–33 (2000).
  CASGoogle Scholar
• 40  Grunstein J, Roberts WG, Mathieu-Costello O, Hanahan D, Johnson RS. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res.59,1592–1598 (1999).
  Medline CASGoogle Scholar
• 41  Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res.60,203–212 (2000).
  Medline CASGoogle Scholar
• 42  Niu G, Wright KL, Huang M et al. Constitutive STAT3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene21,2000–2008 (2002).
  Medline CASGoogle Scholar
• 43  Wei D, Le X, Zheng L et al. STAT3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene22,319–329 (2003).
  Medline CASGoogle Scholar
• 44  Li WC, Ye SL, Sun RX et al. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin. Cancer Res.12,7140–7148 (2006).
  Medline CASGoogle Scholar
• 45  Niu G, Heller R, Catlett-Falcone R et al. Gene therapy with dominant-negative STAT3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res.59,5059–5063 (1999).▪ First validation of STAT3 as a target for cancer therapy in an animal model.
  Medline CASGoogle Scholar
• 46  Bromberg JF, Wrzeszczynska MH, Devgan G et al. STAT3 as an oncogene. Cell98,295–303 (1999).
  Medline CASGoogle Scholar
• 47  Siddiquee KAZ, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res.18(2),254–267 (2008).
  MedlineGoogle Scholar
• 48  Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene19(56),6613–6626 (2000).
  Medline CASGoogle Scholar
• 49  Niu G, Shain K, Huang M et al. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res.61,3276–3280 (2001).
  Medline CASGoogle Scholar
• 50  Turkson J, Ryan D, Kim JS et al. Phosphotyrosyl peptides block STAT3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem.276,45443–45455 (2001).▪ Significant proof that small peptide molecules can block cell transformation through a disruption of STAT3 dimerization.
  Medline CASGoogle Scholar
• 51  Levy DE, Darnell JE Jr. STATs: transcriptional control and biological impact. Nature Rev.3,651–662 (2002).
  CASGoogle Scholar
• 52  Akira S. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene19,2607–2611 (2000).
  Medline CASGoogle Scholar
• 53  Turkson J, Zhang S, Palmer J et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent anti-tumor activity. Mol. Cancer Ther.3,1533–1542 (2004).
  Medline CASGoogle Scholar
• 54  Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent anti-tumor activity against human and murine cancer cells in mice. Cancer Res.63,1270–1279 (2003).
  Medline CASGoogle Scholar
• 55  Kortylewski M, Kujawski M, Wang T et al. Inhibiting STAT3 signaling in the hematopoietic system elicits multicomponent anti-tumor immunity. Nat. Med.11,1314–1321 (2005).
  Medline CASGoogle Scholar
• 56  Catlett-Falcone R, Dalton W, Jove R. STAT proteins as novel target for cancer theraphy. Curr. Opin. Oncol.11(6),490–496 (1999).
  Medline CASGoogle Scholar
• 57  Costantino L, Barlocco D. STAT 3 as a target for cancer drug discovery. Curr. Med. Chem.15,834–843 (2008).▪▪ Earlier review on the state-of-the-art of STAT3 inhibitors.
  Medline CASGoogle Scholar
• 58  Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin. Invest. Drugs18(1),45–56 (2009).
  Medline CASGoogle Scholar
• 59  Becker S, Groner B, Müller CW. Three-dimensional structure of the STAT3b homodimer bound to DNA. Nature394,145–151 (1998).
  Medline CASGoogle Scholar
• 60  Fletcher S, Turkson J, Gunning PT. Molecular approches towards the inhibition of the signal transducers and activator of transcription 3 (STAT3) protein. ChemMedChem8,1159–1168 (2008).
  Google Scholar
• 61  Ren Z, Cabell LA, Schaefer TS, McMurray JS. Identification of a high-affinity phosphopeptide inhibitor of STAT3. Bioorg. Med. Chem. Lett.13,633–636 (2003).
  Medline CASGoogle Scholar
• 62  Timofeeva OA, Gaponenko V, Lockett SJ et al. Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target. ACS Chem. Biol.2(12),799–809 (2007).
  Medline CASGoogle Scholar
• 63  Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membrane. J. Biol. Chem.269,10444–10450 (1994).
  Medline CASGoogle Scholar
• 64  Borghouts C, Kunz C, Delis N, Groner D. Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition. Mol. Cancer Res.6(2),267–281 (2008).
  Medline CASGoogle Scholar
• 65  Dourlat J, Liu WQ, Sancier F et al. A novel nonphosphorylated potential anti-tumoral peptide inhibits STAT3 biological activity. Biochimie91,996–1002 (2009).
  Medline CASGoogle Scholar
• 66  Shuai K, Horvath CM, Huang LH, Qureshi SA, Cowburn D, Darnell JE. Interferon activation of the transcription factor STAT91 involves dimerization through SH2–phosphotyrosyl peptide interactions. Cell76(5),821–828 (1994).
  Medline CASGoogle Scholar
• 67  Vultur A, Cao J, Arulanandam R et al. Cell-to-cell adhesion modulates STAT3 activity in normal and breast carcinoma cells. Oncogene2315,2600–2616 (2004).
  Google Scholar
• 68  Ren Z, Coleman DR, Mandal PK et al. Peptidomimetic inhibitors of STAT3: structure–activity relationships and cellular activity. Presented at: The 16th EORTC-NCI-AACR, Symposium on Molecular Targets and Cancer Therapeutics. Genève, Switzerland, 28 September–1 October 2004.
  Google Scholar
• 69  Shuai K. Regulation of cytokine signaling pathways by PIAS proteins. Cell Res.16,196–202 (2006).
  Medline CASGoogle Scholar
• 70  Borghouts C, Tittmann H, Delis N, Kirchenbauer M, Brill B, Groner B. The intracellular delivery of a recombinant peptide derived from the acidic domain of PIAS3 inhibits STAT3 transactivation and induces tumor cell death. Mol. Cancer Res.8(4),539–553 (2010).
  Medline CASGoogle Scholar
• 71  Turkson J, Kim JS, Zhang S et al. Novel peptidomimetic inhibitors of signal transducers and activator of transcription 3 dimerization and biological activity. Mol. Cancer Ther.3,261–269 (2004).
  Medline CASGoogle Scholar
• 72  Gunning PT, Katt WP, Glenn M et al. Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains. Bioorg. Med. Chem. Lett.17,1875–1878 (2007).
  Medline CASGoogle Scholar
• 73  McMurray JS. Structural basis for the binding of high affinity phosphopeptides to STAT3. Biopolymers Peptide90(1),69–79 (2007).
  Google Scholar
• 74  Schust J, Berg T. A high-throughput fluorescence polarization assay for signal transducers and activator of transcription 3. Anal. Biochem.330,114–118 (2004).
  Medline CASGoogle Scholar
• 75  Mandal PK, Heard PA, Ren Z, Chen X, McMurray JS. Solid-phase synthesis of STAT3 inhibitors incorporating O-carbamoylserine and O-carbamoylthreonine as glutamine mimics. Bioorg. Med. Chem. Lett.17,654–656 (2007).
  Medline CASGoogle Scholar
• 76  Mandal PK, Ren Z, Chen X, Xiong C, McMurray JS. Structure–affinity relationships of glutamine mimics incorporated into phosphopeptides targeted to the SH2 domain of signal transducer and activator of transcription 3. J. Med. Chem.52,6126–6141 (2009).
  Medline CASGoogle Scholar
• 77  Coleman DR, Kaluarachichi K, Ren Z, Chen X, McMurray JS. Solid-phase synthesis of phosphopeptides incorporating 2,2-dimethyloxazolidine pseudoproline analogues: evidence for trans Leu-Pro peptide bonds in STAT3 inhibitors. Int. J. Pept. Res. Ther.14(1),1–9 (2008).
  CASGoogle Scholar
• 78  Chen J, Nikolovska-Coleska Z, Yang CY et al. Design and synthesis of a new, conformationally constrained, macrocyclic small-molecule inhibitor of STAT3 via click chemistry. Bioorg. Med. Chem. Lett.17,3939–3942 (2007).
  Medline CASGoogle Scholar
• 79  Dourlat J, Valentin B, Liu WQ, Garbay C. New synthesis of tetrazolylmethylphenylalanine and O-malonyltyrosine as pTyr mimetics for the design of STAT3 dimerization inhibitors. Bioorg. Med. Chem. Lett.17,3943–3946 (2007).
  Medline CASGoogle Scholar
• 80  Gomez C, Bai L, Zhang J et al. Design, synthesis, and evalutation of peptidomimetics containing Freidinger lactams as STAT3 inhibitors. Bioorg. Med. Chem. Lett.19,1733–1736 (2009).
  Medline CASGoogle Scholar
• 81  Coleman DR, Ren Z, Mandal PK et al. Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor. J. Med. Chem.48,6661–6670 (2005).
  Medline CASGoogle Scholar
• 82  Mandal PK, Liao WSL, McMurray JS. Synthesis of phosphatase-stable, cell-permeable peptidomimetic prodrugs that target the SH2 domain of STAT3. Org. Lett.11(15),3394–3397 (2009).
  Medline CASGoogle Scholar
• 83  Chen J, Bai L, Bernard D et al. Structure-based design of conformationally constrained, cell-permeable STAT3 inhibitors. ACS Med. Chem. Lett.1(2),85–89 (2010).
  MedlineGoogle Scholar
• 84  Weidler M, Rether J, Anke T, Erkel G. Inhibition of interleukin-6 signaling by galiellalactone. FEBS Lett.484,1–6 (2000).
  Medline CASGoogle Scholar
• 85  Shin DS, Kim HN, Shin KD et al. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res.69(1),193–202 (2009).
  Medline CASGoogle Scholar
• 86  Siddiquee K, Gunning PT, Glenn M et al. An oxazole-based small-molecule STAT3 inhibitor modulates STAT3 stability and processing and induces anti-tumor cell effects. ACS Chem. Biol.2(12),787–798 (2007).
  Medline CASGoogle Scholar
• 87  Fletcher S, Singh J, Zhang X et al. Disruption of transcriptionally active STAT3 dimers with nonphosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. ChemBioChem10(12),1959–1964 (2009).
  Medline CASGoogle Scholar
• 88  Gunning PT, Glenn MP, Siddiquee K et al. Targeting protein–protein interactions: suppression of STAT3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders. Chem. Bio. Chem.9(17),2800–2803 (2008).
  Medline CASGoogle Scholar
• 89  Ge J, Wu H, Yao SQ. An unnatural amino acid that mimics phosphotyrosine. Chem. Commun. (Camb.)46(17),2980–2982 (2010).
  Medline CASGoogle Scholar
• 90  Siddiquee K, Zhang S, Guida WC et al. Selective chemical probe inhibitor of STAT3, identified through structure-based virtual screening, induces anti-tumor activity. Proc. Natl Acad. Sci. USA104(18),7391–7396 (2007).
  Medline CASGoogle Scholar
• 91  Zhang X, Yue P, Fletcher S, Zhao W, Gunning PT, Turkson J. A novel small-molecule disrupts STAT3 SH2 domain–phosphotyrosine interactions and STAT3-dependent tumor processes. Biochem. Pharmacol.79(10),1398–1409 (2010).
  Medline CASGoogle Scholar
• 92  Song H, Wang R, Wang S, Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits STAT3 function in breast cancer cells. Proc. Natl Acad. Sci. USA102(13),4700–4705 (2005).
  Medline CASGoogle Scholar
• 93  Fuh B. Sobo M, Cen L et al. LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br. J. Cancer100(1),106–112 (2009).
  Medline CASGoogle Scholar
• 94  Bhasin D, Cisek K, Pandharkar T et al. Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioor. Med. Chem. Lett.18(1),391–395 (2008).
  Medline CASGoogle Scholar
• 95  Lin L, Brian H, Pui-Kai L et al. A novel small molecule, LLL12 inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia12(1),39–50 (2010).
  Medline CASGoogle Scholar
• 96  Cui JR, Jian YJ, Wu YK, Wang SM. Synthesis of potential inhibitors for STAT-3 dimerization. Chinese J. Chem.24,1163–1169 (2006).
  CASGoogle Scholar
• 97  Uehara Y, Mochizuki M, Matsuno K, Haino T, Asai A. Novel high-throughput screening system for identifying STAT3-SH2 antagonists. Biochem. Biophys. Res. Comm.380(3),627–631 (2009).
  Medline CASGoogle Scholar
• 98  Hao W, Hu Y, Niu C et al. Discovery of catechol structural moiety as a STAT3 SH2 domain inhibitor by virtual screening. Bioorg. Chem. Lett.18,4988–4992 (2008).
  Medline CASGoogle Scholar
• 99  Shahani VM, Yue P, Haftchenary S et al. Identification of purine-scaffold small-molecule inhibitors of STAT3 activation by QSAR studies. ACS Med. Chem. Lett.2(1),79–84 (2011).
  Medline CASGoogle Scholar
• 100  Turkson J, Zhang S, Palmer J et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent anti-tumor activity. Mol. Cancer Ther.3(12),1533–1542 (2004).
  Medline CASGoogle Scholar
• 101  Turkson J, Zhang S, Mora LB et al. A novel platinum compound inhibits constitutive STAT3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J. Biol. Chem.280(38),32979–32988 (2005).
  Medline CASGoogle Scholar
• 102  Xu X, Kasembeli MM, Jiang X, Tweardy BJ, Tweardy DJ. Chemical probes that competitively and selectively inhibit STAT3 activation. PLoS One4(3),e4783 (2009).
  MedlineGoogle Scholar
• 103  Matsuno K, Masuda Y, Uehara Y et al. Identification of a new series of STAT3 inhibitors by virtual screening. ACS Med. Chem. Lett.1(8),371–375 (2010).
  Medline CASGoogle Scholar
• 104  Williamson JR. G-quartet structures in telomeric DNA. Annu. Rev. Biophys. Biomol. Struct.23,703–730 (1994).
  Medline CASGoogle Scholar
• 105  Burge S, Parkinson GN, Hazel P, Todd AK, Neidle S. Quadruplex DNA: sequence, topology and structure. Nucleic Acids Res.34(19),5402–5415 (2006).
  Medline CASGoogle Scholar
• 106  Jing N, Zhu Q, Yuan P, Li Y, Mao L, Tweardy DJ. Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol. Cancer Ther.5(2),279–286 (2006).
  Medline CASGoogle Scholar
• 107  Turkson J, Zhang S, Mora LB, Burns A, Sebti S, Jove R. A novel platinum compound inhibits constitutive STAT3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J. Biol. Chem.280(38),32979–32988 (2005).
  Medline CASGoogle Scholar
• 108  Weerasinghe P, Garcia GE, Zhu Q et al. Inhibition of STAT3 activation and tumor growth suppression of nonsmall cell lung cancer by G-quartet oligonucleotides. Int. J. Onc.31,129–136 (2007).
  Medline CASGoogle Scholar
• 109  Leong PL, Andrews GA, Johnson DE et al. Targeted inhibition of STAT3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc. Natl Acad. Sci. USA100,4138–4143 (2003).
  Medline CASGoogle Scholar
• 110  Barton BE, Murphy TF, Shu P, Huang HF, Meyenhofer M, Barton A. Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. Mol. Cancer Ther.3,1183–1191 (2004).
  Medline CASGoogle Scholar
• 111  Hbibi T, Laguillier C, Souissi I et al. Efficient killing of SW480 colon carcinoma cells by a signal transducer and activator of transcription (STAT) 3 hairpin decoy oligodeoxynucleotide – interference with interferon-c-STAT1-mediated killing. FEBS J.276,2505–2515 (2009).
  Medline CASGoogle Scholar
• 112  Zhanga X, Liua P, Zhang B, Wanga A, Yang M. Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells. Cancer Genet. Cytogen.197,46–53 (2010).
  MedlineGoogle Scholar
• 113  Masuda M, Suzui M, Weinstein B. Effect of epigallocatechin-3-gallate on growth, epidermal growyh factor receptor signalling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin. Cancer Res.7,4220–4229 (2001).
  Medline CASGoogle Scholar
• 114  Way TD, Lee JC, Kuo DH et al. Inhibition of epidermal growth factor receptor signaling by Saussurea involucrata, a rare traditional Chinese medicinal herb, in human hormone-resistant prostate cancer PC-3 cells. J. Agric. Food Chem.58(6),3356–3365 (2010).
  Medline CASGoogle Scholar
• 115  Zhou J, Ong C-N, Hur G-M, Shen H-M. Inhibition of the JAK-STAT3 pathway by andrographolide enhances chemosensitivity of cancer cells to doxorubicin. Biochem. Pharmacol.79,1242–1250 (2010).
  Medline CASGoogle Scholar
• 116  Wesolowska O, Kuźdźal M, Štrancar T, Michalak K. Interaction of the chemopreventive agent resveratrol and its metabolite, piceatannol, with model membranes. Biochim. Biophys. Acta1788,1851–1860 (2009).
  Medline CASGoogle Scholar
• 117  Su L, David M. Distinct mechanisms of STAT phosphorylation via the interferon-α/β receptor. Selective inhibition of STAT3 and STAT5 by piceatannol. J. Biol. Chem.275,12661–12666 (2000).
  Medline CASGoogle Scholar
• 118  Sandra MLT, Li F, Rajendran P, Kumar AP, Hui KM, Sethi G. Identification of β-escin as a novel inhibitor of STAT3/JAK2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. J. Pharmacol. Exp. Ther.334,285–293 (2010).
  MedlineGoogle Scholar
• 119  Wang YMX, Yan S, Shen S et al. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells. Cancer Res.69(18),7302–7310 (2009).
  Medline CASGoogle Scholar
• 120  Sandur SK, Pandey MK, Sung B, Aggarwal BB. 5-hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: potential role in chemosensitization. Mol. Cancer Res.8(1),107–118 (2010).
  Medline CASGoogle Scholar
• 121  Ito S, Oyake T, Murai K, Ishida Y. Deguelin suppresses cell proliferation via the inhibition of survivin expression and STAT3 phosphorylation in HTLV-1-transformed T cells. Leukemia Res.34(3),352–357 (2010).
  Medline CASGoogle Scholar
• 122  Dixit D, Sharma V, Ghosh S, Koul N, Mishra PK, Sen E. Manumycin inhibits STAT3, telomerase activity, and growth of glioma cells by elevating intracellular reactive oxygen species generation. Free Radic. Biol. Med.47,364–374 (2009).
  Medline CASGoogle Scholar
• 123  Zhang J, Li L, Kim SH, Hagerman AE, Lu J. Anticancer, antidiabetic and other pharmacologic and biological activities of penta-galloyl-glucose. Pharm. Res.26(9),2066–2080 (2009).
  Medline CASGoogle Scholar
• 124  Hu H, Lee HJ, Jiang C et al. Penta-1,2,3,4,6-O-galloyl-B-D-glucose induces p53 and inhibits STAT3 in prostate cancer cells in vitro and suppresses prostate xenograft tumor growth in vivo. Mol. Cancer Ther.7(9),2681–2691 (2008).
  Medline CASGoogle Scholar
• 125  Agarwal C, Tyagi A, Kaur M, Agarwal R. Silibinin inhibits constitutive activation of STAT3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis28,1463–1470 (2007).
  Medline CASGoogle Scholar
• 126  Sobota R, Szwed M, Kasza A, Bugno M, Kordula T. Parthenolide inhibits activation of signal transducers and activators of trascription (STATs) induced by cytokines of the IL-6 family. Biochem. Biophys. Res. Commun.267,329–333 (2000).
  Medline CASGoogle Scholar
• 127  Del Bano MJ, Lorente J, Castillo J et al. Phenolic diterpenes, flavones, and rosmarinic acid distribution during the development of leaves, flowers, stems, and roots of Rosmarinus officinalis. Antioxidant activity. J. Agric. Food Chem.51,4247–4253 (2003).
  Medline CASGoogle Scholar
• 128  Lai CS, Lee HJ, Ho CT et al. Rosmanol potently inhibits lipopolysaccharide-induced iNOS and COX-2 expression through downregulating MAPK, NF-KB, STAT3 and C/EBP signaling pathways. J. Agric. Food Chem.57,10990–10998 (2009).
  Medline CASGoogle Scholar
• 129  Zhang C, Li B, Gaikwad AS et al. Avicin D selectively induces apoptosis and downregulates p-STAT-3, Bcl-2, and survivin incutaneous T-cell lymphoma cells. J. Invest. Derm.128,2728–2735 (2008).
  Medline CASGoogle Scholar
• 130  Wang Z, Jin H, Xu R, Mei Q, Fan D. Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression. Exp. Mol. Med.41(10),717–727 (2009).
  Medline CASGoogle Scholar
• 131  Lin L, Hutzen B. Zuo M et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res.70(6),2445–2454 (2010).
  Medline CASGoogle Scholar
• 132  Kim BH, Oh SR, Yin CH et al. MS-1020 is a novel small molecule that selectively inhibits JAK3 activity. Br. J. Haematol.148,132–143 (2009).
  MedlineGoogle Scholar
• 133  Kim BH, Yin CH, Guo Q et al. A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells. Mol. Cancer Ther.7(9),2672–2680 (2008).
  Medline CASGoogle Scholar
• 134  Lasho TL, Tefferi A, Hood JD, Verstovsek S, Gilliland DG, Pardanani A. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia22(9),1790–1792 (2008).
  Medline CASGoogle Scholar
• 135  Cotto M, Cabanillas F, Tirado M, Garcia MV, Pacheco E. Epigenetic therapy of lymphoma using histone deacetylase inhibitors. Clin. Transl. Oncol.12(6),401–409 (2010).
  Medline CASGoogle Scholar
• 136  Verstovsek S. Therapeutic potential of JAK2 inhibitors. Hematology1,636–642 (2009).
  Google Scholar
• 137  Lin KL, Su JC, Chien CM et al. Naphtho[1,2-b]furan-4,5-dione disrupts Janus kinase-2 and induces apoptosis in breast cancer MDA-MB-231. Toxicol. In Vitro24(4),1158–1167 (2010).
  Medline CASGoogle Scholar
• 138  Hedvat M, Huszar D, Herrmann A et al. The JAK2 inhibitor AZD1480 potently blocks STAT3 signaling and oncogenesis in solid tumors. Cancer Cell16(6),487–497 (2009).
  Medline CASGoogle Scholar
• 139  Scuto A, Krejci P, Popplewell L et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia DOI: 10.1038/leu.2010.289 (2010) (Epub ahead of print).
  MedlineGoogle Scholar
• 140  Ioannidis S, Lamb ML, Wang T et al. Discovery of 5-chloro-N²-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N⁴-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/STAT pathway. J. Med Chem.54(1),262–276 (2011).
  Medline CASGoogle Scholar
• 141  Verstovsek S, Kantarjian H, Mesa RA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med.363(12),1117–1127 (2010).
  Medline CASGoogle Scholar
• 142  Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. Drugs13(6),394–403 (2010).
  Medline CASGoogle Scholar
• 143  Campas-Moya C. Ruxolitinib: tyrosine-protein kinase JAK2 inhibitor: treatment of myelofibrosis: treatment of myeloproliferative neoplasms: treatment pf psoriasis. Drugs Fut.35(6),457–465 (2010).
  CASGoogle Scholar
• 144  Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia23(8),1441–1445 (2009).
  Medline CASGoogle Scholar
• 145  Burns CJ, Bourke DG, Andrau L et al. Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). Bioorg. Med. Chem. Lett.19(20),5887–5892 (2009).
  Medline CASGoogle Scholar
• 146  Pedranzini L, Dechow T, Berishaj M et al. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res.66(19),9714–9721 (2006).
  Medline CASGoogle Scholar
• 147  Quintás-Cardama A, Manshouri T, Estrov Z et al. Preclinical characterization of atiprimod, a novel JAK2 and JAK3 inhibitor. Invest. New Drugs DOI: 10.1007/s10637-010-9429-z (2010). (Epub ahead of print).
  Google Scholar
• 148  Vazina MA, Shishodia D, Harris D et al. Atiprimod blocks STAT3 phosphorilation and induces apoptosis in multiple myeloma cells. Br. J. Cancer93,70–80 (2005).
  MedlineGoogle Scholar
• 149  Ramakrishnan V, Timm M, Haug JL et al. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant antimyeloma activity and synergizes with common antimyeloma drugs. Oncogene29(8),1190–1202 (2010).
  Medline CASGoogle Scholar
• 150  Yang F, Brown C, Buettner R et al. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Mol. Cancer Ther.9(4),953–962 (2010).
  Medline CASGoogle Scholar
• 151  Sen B, Saigal B, Parikh N, Gallik G, Johnson FM. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res.69(5),1958–1965 (2009).
  Medline CASGoogle Scholar
• 152  Averett Byers L, Sen B, Saigal B et al. Reciprocal regulation of c-Srg and STAT3 in nonsmall cell lung cancer. Clin. Cancer Res.12(22),6852–6861 (2009).
  Google Scholar
• 153  Premkumar DR, Jane EP, Agostino NR, Scialabbar JL, Pollack IF. Dasatinib synergizes with JSI-124 to inhibit growth and migration and induce apoptosis of malignant human glioma cells. J. Carcinog.9(7),1–14 (2010).
  MedlineGoogle Scholar
• 154  Hutzen B, Friedman L, Sobo M et al. Curcumin analogue GO-Y030 inhibits STAT3 activity and cell growth in breast and pancreatic carcinomas. Int. J. Oncol.35(4),867–872 (2009).
  Medline CASGoogle Scholar
• 155  Keinosuke R, Michiro S, Edwin C et al. Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of STAT3 pathway. BMC Cancer10,187–197 (2010).
  MedlineGoogle Scholar
• 156  Dowlati A, Kluge A, Nethery D, Halmos B, Kern J. SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2. AntiCancer Drugs19(1),9–16 (2008).
  Medline CASGoogle Scholar
• 157  Venkatasubbarao K, Choudary A, Freeman JW. Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3 (Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases. Cancer Res.65(7),2861–2871 (2005).
  Medline CASGoogle Scholar
• 158  Horiguchi A, Asano T, Kuroda K et al. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br. J. Cancer102(11),1592–1599 (2010).
  Medline CASGoogle Scholar
• 159  Ren X, Duan L, He Q et al. Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway. ACS Med. Chem. Lett.1(9),454–459 (2010).
  Medline CASGoogle Scholar
• 160  Bhargava A, Vaishampayan UN. Satraplatin: leading the new generation of oral platinum agents. Expert Opin. Investig. Drugs18(11),1787–1797 (2009).
  Medline CASGoogle Scholar
• 161  Gariboldi MB, Ravizza R, Molteni R, Osella D, Gabano E, Monti E. Inhibition of STAT3 increases doxorubicin sensitivity in human metastatic breast cancer cell line. Cancer Lett.258,181–188 (2007).
  Medline CASGoogle Scholar
• 162  Ngan CY, Yamamoto H, Takagi A et al. Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells. Cancer Sci.99(1),129–139 (2008).
  Medline CASGoogle Scholar
• 163  Shin D-S, Masciocchi D, Gelain A et al. Synthesis, modeling, and crystallographic study of 3,4-disubstituted-1,2,5-oxadiazoles and evaluation of their ability to decrease STAT3 activity. Med. Chem. Comm.1(2),156–164 (2010).
  CASGoogle Scholar
• 164  Jougasaki M, Ichiki T, Takenoshita Y, Setoguchi M. Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. Br. J. Pharmacol.159(6),1294–1303 (2010).
  Medline CASGoogle Scholar
• 165  Lee CS, Shin YJ, Won C et al. Simvastatin acts as an inhibitor of interferon γ-induced cycloxygenase-2 expression in human THP-1 cells, but not in murine RAW264.7 cells. Biocell.33(2),107–114 (2009).
  Medline CASGoogle Scholar
• 166  Jung JE, Kim HS, Lee CS et al. Caffeic acid and its synthetic derivative CADPE suppress tumor angiogenesis by blocking STAT3-mediated VEGF expression in human renal carcinoma cells. Carcinogenesis28(8),1780–1787 (2007).
  Medline CASGoogle Scholar
• 167  Masahiro O, Naoko S, Masanobu S et al. 12-O-tetradecanoylphorbol-13-acetate inhibits melanoma growth by inactivation of STAT3 through protein kinase c-activated tyrosine phosphatase(s). J. Biol. Chem.284(44),30416–30423 (2009).
  MedlineGoogle Scholar
• 168  Yiin JJ, Hu B, Schornack PA et al. ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain. Mol. Cancer Ther.9(4),929–941 (2010).
  Medline CASGoogle Scholar
• 169  Uckun FM, Dibirdik I, Qazi S, Yiv S. Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells. Arzneimittelforschung Journal60(4),210–217 (2010).
  Medline CASGoogle Scholar
• 170  Gariboldi MB, Ravizza R, Monti E. The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. Biochem. Pharmacol.80(4),455–462 (2010).
  Medline CASGoogle Scholar
• 171  Yang Y, Takayuki I, Tamotsu T et al. HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Science96(7),425–433 (2005).
  Medline CASGoogle Scholar
• 172  Nelson EA, Walker SR, Kepich A et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood112(13),5095–5102 (2008).
  Medline CASGoogle Scholar
• 173  Kim HW, Kim JL, Lee HK, Hur DY, Yun IH, Kim SD. Enalapril alters expression of key growth factors in experimental diabetic retinopathy. Curr. Eye Res.34(11),976–987 (2009).
  Medline CASGoogle Scholar
• 174  Yu ZY, Huang R, Xiao H et al. Fluacrypyrim, a novel STAT3 activation inhibitor, induces cell cycle arrest and apoptosis in cancer cells harboring constitutively-active STAT3. Int. J. Cancer127(6),1259–1270 (2010).
  Medline CASGoogle Scholar
• 175  Shao W, Growney JD, Feng Y et al. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: defining molecular mechanisms of resistance. Int. J. Cancer127(9),2199–2208 (2010).
  Medline CASGoogle Scholar
• 176  Changyou L, Yan Z, Malabika S et al. Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Mol. Cancer Ther.8(8),2211–2220 (2009).
  MedlineGoogle Scholar
• 177  Korehito K, Nantiga V, Kayono H et al. A redox-silent analogue of tocotrienol acts as a potential cytotoxic agent against human mesothelioma cells. Life Sciences84(19–20),650–656 (2009).
  MedlineGoogle Scholar
• 178  Lau CK, Yang ZF, Lam SP et al. Inhibition of STAT3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. Cancer Biol. Ther.6(12),1900–1907 (2007).
  Medline CASGoogle Scholar
• 179  Selvendiran K, Bratasz A, Tong L, Ignarro LJ, Kuppusamy P. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. Cell Cycle7(1),81–88 (2008).
  Medline CASGoogle Scholar
• 180  Chatterjee PK, Al-Abed Y, Sherry B, Metz CN. Cholinergic agonists regulate JAK2/STAT3 signaling to suppress endothelial cell activation. Am. J. Physiol. Cell Physiol.297(5),C1294–C1306 (2009).
  Medline CASGoogle Scholar
• 181  Lee HS, Han J, Lee SH, Park JA, Kim KW. Meteorin promotes the formation of GFAP-positive glia via activation of the Jak-STAT3 pathway. J. Cell Sci.123(11),1959–1968 (2010).
  Medline CASGoogle Scholar
• 182  Nakaya A, Sagawa M, Muto A, Uchida H, Ikeda Y, Kizaki M. The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-κB activity. Leuk. Res.35(2),243–249 (2010).
  MedlineGoogle Scholar
• 183  McCleese JK, Bear MD, Fossey SL et al. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int. J. Cancer125(12),2792–2801 (2009).
  Medline CASGoogle Scholar
• 201  Government of the USA. WO 2008151037 (2008).
  Google Scholar
• 202  Orchid Research Laboratories Limited. WO 2007042912 (2007).
  Google Scholar
• 203  Baylor College Medicine. WO 2006069001 (2006).
  Google Scholar
• 204  University of Central Florida Research Foundation, Inc. WO 2010033685 (2010).
  Google Scholar
• 205  H. Lee Moffitt Cancer Center & Research Institute. WO 2007136858 (2007).
  Google Scholar
• 206  Farjo R. WO 2009042677 (2009).
  Google Scholar
• 207  Baylor College Medicine. WO 2009149192 (2009).
  Google Scholar
• 208  Pharma IP General Incorporate Association. WO 2010004761 (2010).
  Google Scholar
• 209  Univesity of South Florida. WO 2007US2827 (2007).
  Google Scholar
• 210  Supergen, Inc. WO 2010011349 (2010).
  Google Scholar
• 211  Orchid Research Laboratories Limited. WO 2007042912 (2007).
  Google Scholar
• 212  Orchid Research Laboratories Limited. WO 2009060282 (2009).
  Google Scholar
• 213  Boston Biomedical, Inc. WO 2009036059 (2009).
  Google Scholar
• 214  Otsuka Pharmaceutical Co, Ltd. WO 2009057811 (2009).
  Google Scholar
• 215  Board of Regents, the Univesity of Texas System. WO 2010005807 (2010).
  Google Scholar
• 216  Kwon BM. US 20080051442 (2008).
  Google Scholar